Original regimen of subcutaneous interleukin 2 (IL2) and interferon alpha (IFN) in patients with metastatic renal cell carcinoma (MRCC) ineligible to receive intravenous (iv) IL2

被引：0
|
作者：
Escudier, B [1 ]
Rossi, JF [1 ]
Ravaud, A [1 ]
Savary, J [1 ]
Pignard, K [1 ]
Negrier, S [1 ]
机构：
[1] CTR LEON BERARD,FRANCH CANC CTR FEDERAT,CTR COORDINATING,IMMUNOTHERAPY GRP,F-69373 LYON,FRANCE
来源：
EUROPEAN JOURNAL OF CANCER | 1995年 / 31A卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：470 / 470
页数：1
相关论文
共 50 条
  • [21] COAGULATION ABNORMALITIES ASSOCIATED WITH INTERLEUKIN-2 (IL2) THERAPY FOR METASTATIC CANCER
    STRACK, M
    GRIMA, K
    SUSSMAN, I
    DUTCHER, J
    WIERNIK, P
    CLINICAL RESEARCH, 1990, 38 (03): : A776 - A776
  • [22] Subcutaneous (SC) interleukin-2 (IL-2) plus alpha interferon (IFN-alpha) and 5 fluorouracil (5FU) in out-patients (pts) with metastatic renal cell carcinoma (MRCC). Scapp II trial
    Tourani, JM
    Benhammouda, A
    Guillet, P
    Pfister, C
    Paule, B
    Berbah, JF
    Chretien, Y
    Salze, P
    Monnier, A
    Brewer, Y
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 150 - 150
  • [23] ACUTE ALITHIASIC CHOLECYSTITIS IN PATIENTS GIVEN INTERLEUKIN-2 (IL2)
    LEVY, R
    CARGILL, M
    LEMAIGNAN, C
    NDAW, D
    ANDRIEU, JM
    PRESSE MEDICALE, 1994, 23 (34): : 1583 - 1583
  • [24] COMBINATION OF IL2 AND IFN-ALPHA A/D - ANTITUMOR AND IMMUNOMODULATORY ACTIVITY
    FINKE, J
    LEWIS, I
    TUBBS, R
    GANAPATHI, R
    LYMPHOKINE RESEARCH, 1987, 6 (01): : U112 - U112
  • [25] PHASE-I TRIAL OF THE COMBINATION OF GAMMA INTERFERON (GAMMA-IFN) AND INTERLEUKIN 2 (IL2) IN ADVANCED MALIGNANCY
    MAZUMDER, A
    WATKINS, K
    AGAH, R
    HU, E
    JOURNAL OF BIOLOGICAL RESPONSE MODIFIERS, 1989, 8 (03): : 305 - 306
  • [26] IL2 WITH OR WITHOUT LAK CELLS IN METASTATIC RENAL-CARCINOMA AND NEURO-BLASTOMA
    PHILIP, T
    MERCATELLO, A
    COCHAT, P
    TOGNIER, E
    COMBARET, V
    GASPARD, M
    FAVROT, M
    PHILIP, I
    MOSKOVTCHENKO, JF
    BIJMAN, JT
    FRANKS, C
    FLORET, D
    LYMPHOKINE RESEARCH, 1988, 7 (03): : 331 - 331
  • [27] Tumor cell responsiveness to IFN-γ contributes to IL2/IL12 immunotherapy
    Shorts, L
    Briggs, L
    Back, T
    Wiltrout, R
    FASEB JOURNAL, 2004, 18 (05): : A1154 - A1154
  • [28] Subcutaneous interleukin-2 and interferon in the treatment of patients with metastatic renal cell carcinoma -: Less efficacy compared with intravenous interleukin-2 and interferon α
    Ravaud, A
    Delva, R
    Gomez, F
    Chevreau, C
    Douillard, JY
    Peny, J
    Coudert, B
    Négrier, S
    CANCER, 2002, 95 (11) : 2324 - 2330
  • [29] CONTINUOUS INTRAVENOUS INTERLEUKIN-2 INFUSION AND SUBCUTANEOUS INTERFERON-ALPHA IN METASTATIC RENAL-CELL CARCINOMA
    FOSSA, SD
    AUNE, H
    BAGGERUD, E
    GRANERUD, T
    HEILO, A
    THEODORSEN, L
    EUROPEAN JOURNAL OF CANCER, 1993, 29A (09) : 1313 - 1315
  • [30] CORRELATION BETWEEN CYTOKINE SERUM LEVELS AND RESPONSE TO IL2 IN PATIENTS WITH RENAL-CELL CARCINOMA
    BLAY, JY
    COMBARET, V
    NEGRIER, S
    FRANKS, CR
    MERCATELLO, A
    PHILIP, T
    FAVROT, M
    EXPERIMENTAL HEMATOLOGY, 1991, 19 (06) : 502 - 502
12345